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The tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10) and the
androgen receptor (AR) play important roles in tumor development and progression in prostate carcinogen-
esis. Among many functions, PTEN negatively regulates the cytoplasmic phosphatidylinositol-3-kinase/AKT
anti-apoptotic pathway; and nuclear PTEN affects the cell cycle by also negatively regulating the MAPK path-
way via cyclin D. Decreased PTEN expression is correlated with prostate cancer progression. Over-
expression of AR and upregulation of AR transcriptional activity are often observed in the later stages of
prostate cancer. Recent studies indicate that PTEN regulates AR activity and stability. However, the mechan-
ism of how AR regulates PTEN has never been studied. Furthermore, resveratrol, a phytoalexin enriched in
red grapes, strawberries and peanuts, has been shown to inhibit AR transcriptional activity in prostate cancer
cells. In this study, we use prostate cancer cell lines to test the hypothesis that resveratrol inhibits cellular
proliferation in both AR-dependent and -independent mechanisms. We show that resveratrol inhibits AR tran-
scriptional activity in both androgen-dependent and -independent prostate cancer cells. Additionally, resver-
atrol stimulates PTEN expression through AR inhibition. In contrast, resveratrol directly binds epidermal
growth factor receptor (EGFR) rapidly inhibiting EGFR phosphorylation, resulting in decreased AKT phos-
phorylation, in an AR-independent manner. Thus, resveratrol may act as potential adjunctive treatment for
late-stage hormone refractory prostate cancer. More importantly, for the ﬁrst time, our study demonstrates
the mechanism by which AR regulates PTEN expression at the transcription level, indicating the direct link
between a nuclear receptor and the PI3K/AKT pathway.
INTRODUCTION
Prostate cancer is the most common cancer and the second
leading cause of cancer mortality among men in the western
world. In 2009, there were192 280 estimated new cases and
27 360 deaths in the USA (1). Prostate tumors are initially
dependent on androgens for growth, but the majority of
patients treated with anti-androgen therapy progress to
androgen independence characterized by resistance to such
treatment, portending a poor prognosis. The mechanism of
progression to androgen independence remains unclear and,
so far, there is no effective treatment for hormone-refractory
prostate cancer.
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Advance Access published on August 20, 2010The androgen receptor (AR) belongs to the nuclear recep-
tor superfamily and can act as a transcription factor. AR is
known to play important roles in reproductive system
development and prostate cancer progression. In its inactive
form, AR forms a complex with Hsp90/70 in the cytoplasm
(2). Presence of ligand, such as dihydrotestosterone (DHT),
induces AR phosphorylation and conformational change,
resulting in its nuclear translocation and target-gene
regulation. Over-expression of AR and upregulation of its
transcriptional activity are often observed in advanced
prostate cancer (3,4). Teleologically, this provides prostate
cancer cells with a potential survival advantage under the
low androgen levels after androgen deprivation
treatment, and so, leads to progression to hormone refrac-
tory disease.
The tumor suppressor gene PTEN (phosphatase and tensin
homolog deleted on chromosome 10), located on chromo-
some sub-band 10q23, is one of the most frequently
mutated genes in a broad variety of human cancers (5).
Through its phospholipid 3-phosphatase activity, PTEN
negatively regulates the (PI3K)/AKT pathway, which is
involved in cell proliferation, migration and apoptosis.
Recently, it has been shown that PTEN can translocate
into the nucleus, functioning as a protein phosphatase (6).
Loss of PTEN expression is frequently found in prostate
cancer cell lines and human non-cultured tumor specimens
(7). As a result, AKT phosphorylation and activity are sig-
niﬁcantly increased, especially in androgen-independent
prostate cancers (8). PTEN inhibits phosphorylation of
AKT that, in turn, stimulates AR phosphorylation and
activity (9). In addition, PTEN also directly interacts with
the AR DNA-binding domain/Hinge domain and inhibits
AR nuclear translocation and AR-mediated transcriptional
activity (10). However, the inverse correlation of AR and
PTEN expression in prostate cancers is not fully understood,
which led us to hypothesize that AR must regulate PTEN to
complete a feedback loop. Resveratrol (3,4′,5-trihydroxystil-
bene), a phytoalexin, commonly exists in a wide variety of
fruits and plants, such as grapes, peanuts and raspberries
(11). Among them, black-grape skin contains high concen-
trations of resveratrol, with the latter a major constituent
of red wine. Epidemiologic studies have demonstrated the
positive effect of resveratrol on lowering the risk of cardio-
vascular disease and certain cancers (12,13). In vitro, resver-
atrol has also been shown to inhibit proliferation of several
types of cancer cells (14–16). There is sufﬁcient promise
that clinical trails are being carried out to determine the
effectiveness of resveratrol treatment for skin and colon
cancer.
We showed in our previous report that resveratrol
increases PTEN expression in breast cancer cell lines and
inhibits proliferation (17), together with recent observations
that resveratrol inhibits AR transcriptional activity in
androgen-dependent LNCaP prostate cancer cells (18).
Therefore, we sought to ﬁrst determine the role of
resveratrol on prostate cancer cell proliferation in the
context of AR-dependent and -independent pathways, and
then to utilize resveratrol to interrogate the precise mechan-
ism of AR regulation of PTEN and prostate cancer cell
proliferation.
RESULTS
Resveratrol inhibits proliferation in both
androgen-dependent and -independent prostate
cancer cell lines
We ﬁrst began by analyzing the effect of resveratrol on pros-
tate cancer cell proliferation. We treated androgen-dependent
LNCaP cells and its androgen-independent sub-clone, C4-2
cells, with three different dosages of resveratrol for 5 days,
and measured growth each day. The chosen dosages, which
were based on reported resveratrol concentration in red
wine, have been widely used in previous studies (19,20).
Growth of both androgen-dependent and -independent prostate
cancer cells was inhibited by resveratrol, an effect that was
obvious by Day 3 (Fig. 1A). We have selected three doses
of resveratrol to include the believed physiological concen-
tration after consumption of one to two glasses of red wine
(usually accepted as 10–20 mM) and two points, one at
either extreme. Accordingly, we have selected 10 mM to rep-
resent post-red wine consumption, and 1 mM for the lower
end and 50 mM the upper extent. To determine whether other
isoﬂavones affect prostate cancer cell growth, we treated
LNCaP and C4-2 cells with Formononetin (Fig. 1B) or Bio-
chanin A (Fig. 1C). Both drugs inhibited cell proliferation
(Fig. 1B and C). Because there was evidence that 25 mM
resveratrol induces S phase arrest in normal prostate epithelial
cells (13), we treated LNCaP and C4-2 cells with this dose of
resveratrol for 48 h followed by ﬂow cytometry. This revealed
S phase arrest in both androgen-dependent and -independent
prostate cancer cells, while no changes in apoptosis capacity
were noted (Fig. 1D). We also analyzed the cell cycle and
apoptosis after 24 h of resveratrol exposure, with similar
results (data not shown).
Resveratrol inhibits the AR pathway in prostate
cancer cells
Next, we analyzed the effect of resveratrol on AR in both
androgen-dependent LNCaP and androgen-independent C4-2
cells. We transfected each cell with a reporter plasmid, con-
taining a promoter comprising six copies of androgen receptor
response elements (AREs) tagged with a luciferase reporter
gene. Luciferase assays showed that AR transcriptional
activity was inhibited by resveratrol at both 10 and 50 mM con-
centrations in both LNCaP and C4-2 cells, while low concen-
trations of resveratrol (1 mM) slightly, but not signiﬁcantly,
increased AR activity in LNCaP (Fig. 2A). The expression
of PSA transcript, which is regulated by AR, was inhibited
by resveratrol (Supplementary Material, Fig. S1). Also, resver-
atrol inhibited the endogenous PSA protein expression at the
two higher doses in both LNCaP and C4-2 cells (Fig. 2A,
insert). DHT signiﬁcantly increased AR transcriptional
activity in both LNCaP and C4-2 cells, an effect that was abro-
gated by resveratrol (Fig. 2B and C). In contrast, an anti-AR
drug bicalutamide (Casodex) inhibited AR activity, and
resveratrol further enhanced this inhibitory effect (Fig. 2B
and C).
As both Casodex and resveratrol inhibit AR activity, we
next used LNCaP cells to see their effect on cell proliferation.
Although 10 mM resveratrol or 10 mM Casodex induced similar
4320 Human Molecular Genetics, 2010, Vol. 19, No. 22levels of AR inhibition (Fig. 2B), resveratrol had a more sig-
niﬁcant (P ¼ 0.048) effect on cell growth (57% inhibition)
compared with Casodex (46% inhibition) (Fig. 2D). We also
found that the combination of resveratrol and Casodex
showed the same inhibition ratio as resveratrol itself
(Fig. 2D). These data imply that resveratrol may inhibit cell
growth through a secondary mechanism independent of the
AR pathway.
Resveratrol induces PTEN transcription by AR inhibition
in prostate cancer cells
Resveratrol has recently been shown to induce PTEN protein
expression in MCF-7, a breast cancer cell line (17). Clinical
observations note that AR levels correlated with PTEN
protein expression and that the ratio between the two proteins
by immunohistochemistry is correlated with patient survival
and outcome (21). At the same time, AR over-expression
and hyper-activity are often observed in androgen-independent
prostate cancer in response to anti-androgen therapy (3,22).
Our data above demonstrate that resveratrol (often considered
a phyto-estrogen), acting as a weak estrogen, inhibits AR tran-
scriptional activity in both androgen-dependent LNCaP cells
and androgen-independent C4-2 cells (Fig. 2B and C). We
then set out to determine the relationship of resveratrol-
regulated AR activity on PTEN transcription. Androgen-
independent C4-2 cells were transfected with PTEN promoter
reporter plasmid and treated with 10 mM resveratrol combined
Figure 1. Resveratrol inhibits prostate cancer cell proliferation. (A) Effect of resveratrol on LNCaP (left panel) and C4-2 (right panel) cell proliferation. Fifteen
thousand cells were plated in each of 24-well plates in complete medium (FBS) and treated with DMSO (control) or different concentrations of resveratrol.
Growth rates of the cells were assessed by MTT assay over a period of 5 days. Each growth-data point represents a mean value of three experiments and
the error bars indicate the standard deviation, unless otherwise indicated. A Jonckheere–Terpstra trend test was performed to evaluate alternatives of
ordered class differences by dose concentrations (P , 0.001). All statistical tests were two sided. Both cell lines show growth inhibition in response to increasing
resveratrol doses. (B) Effect of Formononetin (P , 0.01) and (C) Biochanin A (P , 0.001) on LNCaP and C4-2 cell growth rates as assessed by the MTT assay.
Molecular structures of the three phytoestrogens are shown as inserts on the right of the growth curves. (D) Flow cytometric analysis of the effects of resveratrol
on proliferation and apoptosis (sub-G1). LNCaP and C4-2 cells were treated with 25 mM resveratrol for 48 h, ethanol-ﬁxed, stained with propidium iodide and
subjected to ﬂow cytometry. The fraction of cells in the different phases of the cell cycle and those undergoing apoptosis was measured as described.
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Resveratrol signiﬁcantly stimulated PTEN promoter activity
3-fold (Fig. 3A). Interestingly, we found that DHT decreased
PTEN promoter activity and mitigated resveratrol-induced
PTEN promoter activity in a dose-dependent manner
(Fig. 3A). In contrast, Casodex alone dramatically increased
PTEN promoter activity to similar levels as that of resveratrol
alone or both Casodex and resveratrol (Fig. 3A). To further
conﬁrm our observations here suggesting that AR regulates
the PTEN promoter, we knocked down AR by transfecting
C4-2 cells with anti-AR siRNA. AR siRNA signiﬁcantly
decreased AR expression (Fig. 3B, insert) and increased
PTEN promoter activity 2.5-fold (Fig. 3B). Furthermore,
additional treatment with DHT or Casodex after AR knock-
down could not further regulate PTEN promoter activity
(Fig. 3B). Taken together, therefore, our data here suggest
that resveratrol-induced PTEN transcription is mediated by
AR inhibition, at least in prostate cancer cells.
To further conﬁrm that resveratrol-induced PTEN promo-
ter activity is mediated by AR, AR-positive C4-2 cells and
AR-negative DU145 cells were transfected with PTEN-
promoter reporter plasmids and treated with resveratrol.
Reporter constructs included a full-length PTEN promoter
21344 to 21 and truncated PTEN promoter 21344 to
21001 (Fig. 3C, left panel). Both PTEN promoter con-
structs, the full-length as well as the 21344 to 21001 seg-
ments, could be activated by resveratrol exposure in
AR-positive C4-2 cells (Fig. 3C). In contrast, these two
PTEN promoter constructs did not respond to resveratrol
exposure in AR-negative DU145 cells (Fig. 3C). Our data
indicate that the resveratrol-associated PTEN promoter
activity is AR-dependent and this regulation is mediated
by the 21344 to 21001 region of the PTEN promoter.
We then proceeded to compare resveratrol-regulated
endogenous PTEN expression in AR-positive CWR22rv1
cells and AR-negative DU145 cells, the only two prostate
cancer cell lines that express endogenous PTEN.
CWR22rv1 cells treated with different concentrations of
resveratrol showed increased PTEN expression and
decreased AKT phosphorylation, while the PTEN levels in
DU45 cell did not change after similar treatment (note
DU145 cells do not express phospho-AKT) (Fig. 3D). Our
observations from this series of experiments demonstrate
that AR, acting as a transcriptional repressor, downregulates
PTEN promoter activity in prostate cancer cells. Thus, inhi-
bition of AR by resveratrol releases PTEN promoter activity
and stimulates PTEN protein expression in the prostate
cancer cells.
Figure 2. Resveratrol inhibits AR transcriptional activity. (A) LNCaP and C4-2 cells were co-transfected with plasmids expressing hARE-Luc and Renilla-Luc
and treated with DMSO (control) and different concentrations of resveratrol for 48 h before lysis of cells for luciferase assay. Data represent mean luciferase
ﬁreﬂy luminescence + SD (n ¼ 3) normalized to Renilla-luminescence. Right panel shows western blots demonstrating increasing concentrations of resveratrol
associated with decreasing PSA expression in LNCaP cells. Parenthetically, at the 1 mM concentration, resveratrol may have slightly increased AR transcriptional
activity and PSA expression in LNCaP cells. (B) LNCaP and (C) C4-2 cells were transfected with plasmids expressing hARE-Luc and Renilla-Luc and treated as
indicated. AR activity was then measured by luciferase assay (∗P , 0.005). (D) LNCaP cells were treated with DMSO (control) or different concentrations of
resveratrol. Growth rate of the cells was assessed by the MTT assay over a period of 5 days. Note that resveratrol and Casodex induced cell growth inhibition and
the two-drug combination had the same effect as resveratrol by itself (∗P , 0.01).
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Our data above suggest that resveratrol inhibits proliferation
through the AR in both androgen-dependent and -independent
prostate cancer cells. In order to examine whether resveratrol
has a similar effect on cell proliferation in AR-negative pros-
tate cancer cells, we treated DU145, an AR-negative
androgen-independent prostate cancer cell line, with
Figure 3. Resveratrol-induced PTEN promoter activity is mediated by AR. (A) C4-2 cells were co-transfected with plasmids expressing PTEN-Luc/Renilla-Luc
and treated as indicated for 48 h. PTEN promoter activity was measured by dual luciferase assay. AR-ligand DHT inhibited PTEN promoter activity in a dose-
dependent manner and resveratrol stimulated PTEN promoter activity. In contrast, AR-antagonist Casodex was shown to stimulate PTEN promoter activity, with
resveratrol only adding slightly to this effect (∗P , 0.005). (B) Knockdown of AR results in increased PTEN promoter activity. C4-2 cells were co-transfected
with control siRNA or anti-AR siRNA and PTEN-luc/Renilla-Luc plasmids. After 48 h of treatment, PTEN promoter activity was measured by luciferase assay.
The insert shows the knockdown of AR protein expression (∗P , 0.005). (C) DU145 and C4-2 cells were transfected with PTEN-Luc/Renilla-Luc plasmids.
Cells were treated with DMSO, or 10 mM resveratrol for 48 h. PTEN promoter activity was measured by luciferase assay. The structures of the 21134 to
21 and truncated 21134 to 21001 PTEN promoters are shown on the left panel. (D) AR-negative DU145 and AR-positive CWR22rv1 cells were treated
with DMSO, 10, 20 or 50 mM resveratrol for 48 h. Western blots show PTEN, phospho-AKT, total-AKT and Actin levels. The quantiﬁcation of phospho-AKT
is shown in Supplementary Material, Fig. S3. Note that resveratrol did not change PTEN levels in DU145 cells.
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centration, cell proliferation showed signiﬁcant decreases, an
effect that was visible at 3 days (Fig. 4A). These observations
suggest that resveratrol can induce AR-independent growth
inhibition as well. The ﬂow cytometry data also indicated
that 50 mM resveratrol could induce apoptosis in DU145 (Sup-
plementary Material, Fig. S2).
Upregulated AKT signaling has been correlated with both
prostate cancer development and androgen-independent pro-
gression (8). Resveratrol has been shown to decrease AKT
phosphorylation in LNCaP cells, but there was no evidence
to support a direct effect (23). Our data above showed that
resveratrol increased PTEN expression and decreased AKT
phosphorylation in CWR22rv1 cells. Based on these obser-
vations and knowing that upregulation of epidermal growth
factor receptor (EGFR) and human epidermal growth factor
receptor 2 (HER2)/NEU in breast cancer cells result in
AKT phosphorylation and increased signaling (24,25), we
sought to determine whether our AR-independent resveratrol
effect in prostate cancer cells was mediated via member(s) of
the EGFR family leading to downstream AKT pathway sig-
naling. After resveratrol treatment, AR-negative DU145 cells
showed signiﬁcant inhibition of EGFR1 (Tyr1068) and
EGFR2/HER2 (Tyr1221/1222) phosphorylation (Fig. 4B).
Interestingly, we did not observe changes at other EGFR
phosphorylation sites, including Tyr845, Tyr992 and
Tyr1045 (data not shown). The prostate cancer cells also
showed decreased extracellular signal-regulated kinase
(ERK) phosphorylation likely due to decreased total ERK
protein expression (Fig. 4B). We then examined resveratrol’s
effect on EGFR and HER2 and downstream AKT phos-
phorylation in AR-positive prostate cancer cells. After 48 h
exposure of androgen-dependent LNCaP cells and androgen-
independent C4-2 cells to resveratrol, phosphorylation of
EGFR, HER2 and AKT was signiﬁcantly decreased
(Fig. 4C). In fact, this effect was more marked in the
androgen-independent sub-clone C4-2 over the primary
androgen-dependent LNCaP cells. These results suggest
that resveratrol-induced downregulation of AKT phosphoryl-
ation may be independent of PTEN levels in prostate
cancer cells.
Our observations above on prostate cancer cells and pre-
vious study in breast cancer cells corroborate that resveratrol
treatment decreases AKT and ERK phosphorylation (17).
However, the mechanism of how resveratrol regulates cell
signaling is still unclear. Therefore, to determine whether
resveratrol downregulates EGFR phosphorylation resulting
in inhibition of its downstream pathways, C4-2 cells were
treated with 10 mM resveratrol for a total 4 days (Fig. 5A).
Time-course experiments revealed that phosphorylation of
Figure 4. Resveratrol inhibits cell proliferation in AR-negative prostate caner cells. (A) Resveratrol inhibits AR-negative DU145 cell proliferation. DU145 cells
were treated with DMSO (control) or increasing concentrations of resveratrol. Growth rate of the cells was assessed by MTT assay over a period of 1–5 days.
(B) DU145 cells were treated with DMSO, and 10, 20 or 50 mM resveratrol. Western blots show resveratrol decreased phosphorylation of EGFR-Tyr1068 (upper
panel), HER2-Tyr1221/1222 (second panel). (C) LNCaP and C4-2 cells were treated with DMSO, and 1, 10, 20 or 50 mM resveratrol. Resveratrol decreased
EGFR (Tyr1068), HER2 (Tyr1221/1222) and AKT phosphorylation. The quantiﬁcations of protein phosphorylation are shown in Supplementary Material,
Fig. S4.
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treatment (Fig. 5A). Downstream AKT phosphorylation was
not decreased until 1 min of treatment (Fig. 5A). In addition,
PTEN protein expression was signiﬁcantly increased after
8 h of treatment (Fig. 5A). The AKT phosphorylation level
was further decreased after PTEN upregulation. We did not
observe decreased ERK phosphorylation induced by resvera-
trol in prostate cancer cells, a phenomenon that has been
reported in breast cancer cells (26–28). The rapid effect of
resveratrol suggests that resveratrol may directly inhibit
EGFR and HER2 phosphorylation, resulting in the deactiva-
tion of downstream AKT pathways. To conﬁrm resveratrol’s
direct effect on EGFR and HER2, we ﬁrst treated C4-2 cells
with 1 ng/ml of EGF combined with different concentrations
of resveratrol. As we expected, EGF signiﬁcantly increased
EGFR and HER2 phosphorylation and its downstream AKT
phosphorylation (Fig. 5B, comparing lane 6 to lane 1). In
addition, EGF treatment abrogated resveratrol’s inhibitory
Figure 5. Resveratrol inhibits EGFR/HER2 signaling pathway. (A) Time course of resveratrol treatment of CWR22rv1 cells. Cells were treated with 10 mM
resveratrol and cell lysates were harvested at each time point indicated. EGFR, HER2 and AKT phosphorylation are signiﬁcantly decreased after the treatment.
Resveratrol also stimulates PTEN protein expression. (B) C4-2 cells were cultured with DMSO, and 1, 10, 20 or 50 mM resveratrol for 48 h. After 3 min of
DMSO or EGF (1 ng/ml) treatment, cells were harvested and subjected to western blot. EGF abrogated resveratrol’s effect on EGFR, HER2 and AKT phos-
phorylation. (C) Emission ﬂuorescence of resveratrol (5 mM) in PBS in the context of water as control, 1 mM BSA, 1 mM EGFR or 1 mM EGFR (672-1210)
at pH 7.0. Excitation wavelength is 334 nm and resveratrol’s emission ﬂuorescence peaked at 392 nm. (D) Schematic model depicting the mechanism by
which resveratrol inhibits proliferation in both AR-dependent and -independent mechanisms. Resveratrol inhibits AR transcriptional activity and PSA expression.
In contrast, it inhibits phosphorylation of EGFR and HER2, rapidly suppressing downstream AKT pathways. Resveratrol lifts AR repression of PTEN promoter
resulting in PTEN transcription and a later-effect suppression of AKT signaling. The quantiﬁcations of protein phosphorylation are shown in Supplementary
Material, Fig. S5.
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paring lanes 6–10 to lanes 1–5).
Furthermore, we used a ﬂuorescence assay to analyze the
physical interaction between resveratrol and EGFR. As
reported previously, resveratrol, containing a stilbene struc-
ture, has an emission ﬂuorescence peak at 392 nm and the
excitation wavelength of 344 nm (29,30). After incubation
with 1 mM EGFR, resveratrol’s ﬂuorescence intensity was sig-
niﬁcantly increased, while the same concentration of BSA did
not affect its ﬂuorescence emission (Fig. 5C). This result
suggests that EGFR directly binds multiple resveratrol
molecules, resulting in the enhanced ﬂuorescence intensity.
Interestingly, truncated EGFR (672-1210), without the extra-
cellular ligand-binding domain and transmembrane domain,
did not interfere with resveratrol’s ﬂuorescence emission. As
a strong hydrophilic compound, resveratrol is unlikely to
interact with the hydrophobic transmembrane domain of
EGFR, indicating that the ligand-binding domain of EGFR
is necessary for resveratrol binding (Fig. 5C). Overall, our
observations indicate that resveratrol may directly inhibit
EGFR signaling, which, in turn, downregulates the AKT
pathway.
DISCUSSION
For many decades, anecdotal observations and clinical epide-
miologic studies conﬁrm that red wine has beneﬁcial effects in
lowering the risk of cardiovascular diseases and some cancers
(31–33). Recent studies revealed that resveratrol, an important
component of red wine, also has the ability to inhibit growth
and induce apoptosis in various kinds of tumor cells, such as
prostate cancer, breast cancer and melanoma (15,34,35).
Resveratrol commonly exists in many types of food, such as
peanuts, cranberries and grapes, making it a good candidate
as a natural chemopreventive or therapeutic adjunct against
cancer (11). Several potential targets of resveratrol have
been reported, including NF-kappa B, AP-1, p53, Bcl-2 and
Bax (15,16,35,36). However, the mechanism by which resver-
atrol inhibits cancer cell growth is still not fully understood.
For certain cancers, epidemiologic studies have not been con-
clusive whether red wine is beneﬁcial or detrimental (37–39).
If the opposing studies are well controlled, then one may
surmise from these observations that the local milieu,
whether hormonal or otherwise, might be important.
In this study, we used prostate cancer cells to demonstrate
that resveratrol inhibits proliferation via both AR-dependent
and -independent mechanisms (Fig. 5D). Our data showed
that resveratrol not only inhibits AR activity but also inhibits
EGFR and HER2 phosphorylation with consequent decreased
AKT phosphorylation in both androgen-dependent and
-independent prostate cancer cells. Notably, we have shown,
for the ﬁrst time, that resveratrol stimulates PTEN promoter
activity via AR, resulting in upregulation of both PTEN tran-
script and protein expression.
One of the biggest challenges in the treatment of advanced
prostate cancer is lack of effective therapy for the hormone
refractory tumor, which is resistant to androgen deprivation
therapy. Previous reports showed that androgen-independent
prostate cancers have a hyper-activated PI3K/AKT pathway
resulting in increased proliferation (40,41). As a result, these
carcinoma cells attain a growth advantage after hormone
deprivation with cellular proliferation becoming independent
of androgen levels. We show here that resveratrol inhibits pro-
liferation in both AR-positive and -negative prostate cancer
cells through not only AR-dependent but also, and impor-
tantly, AR-independent pathways, suggesting that resveratrol
may be a plausible candidate for adjunctive therapy in
hormone-independent advanced prostate cancers.
Recent studies found that resveratrol inhibits AKT and
MAPK cell signaling pathways (23,27). However, the mech-
anism of how resveratrol regulates those pathways remains
unclear. A previous study showed that resveratrol is able to
reduce HCMV-induced EGFR auto-phosphorylation in
human embryonic lung ﬁbroblasts (42). Here, we found that
resveratrol inhibits EGFR and HER2 phosphorylation, result-
ing in decreased AKT phosphorylation and this effect is inde-
pendent of AR. Interestingly, we noticed that high dose of
resveratrol inhibited ERK phosphorylation, most likely due
to the decreased total protein level in DU145 cells but not
other cell lines we tested. Further study is needed to investi-
gate the mechanism. EGFR family members play critical
roles in cancer development and progression. After binding
with EGF, EGFR undergoes dimerization, auto-phosphoryl-
ation and activation in response to ligand binding, resulting
in activation of its downstream cell signaling pathways, such
as those of AKT and MAPK. Phosphorylation of EGFR
provides binding sites for Grb2 and Gab1 (43,44). Grb2 then
induces downstream MAPK/ERK cascades, while Gab1
induces p85 phosphorylation, resulting in the activation of
AKT (45,46). HER2/NEU activation leads to activation of
PI3K/AKT pathway, which has been shown to phosphorylate
AR at Ser213 and Ser791 (9). Meanwhile, HER2/NEU could
also regulate AR through activating MAPK pathway (25).
Notably, we have shown, for the ﬁrst time, that resveratrol
binds directly to multiple docking sites of the extracellular
portion of EGFR, thus explaining the rapid dephosphorylation
of EGFR on Tyr-1068, with consequent downregulation of
AKT signaling. We also found that phosphorylation of
HER2 (Tyr1221/1222) and HER3 (Tyr1289) (data not
shown) was decreased by resveratrol. However, we did not
observe any change in ERK phosphorylation, which has
been reported in at least one other study (27). In contrast,
resveratrol stimulates PTEN protein expression 8–12 h after
exposure, suggesting that consequent decrease in AKT phos-
phorylation (1 min after treatment) is a result of signaling
mainly from resveratrol’s effect on dowregulating EGFR.
Taken together, these observations in toto suggest a bimodal
temporal AKT response to resveratrol exposure, an
AR-independent rapid response via direct binding to and
downregulation of EGFR, and a later response via
AR-mediated upregulation of PTEN. We also recognize the
challenges for using resveratrol in vivo in direct patient treat-
ment because of its low bioavailability due to rapid metab-
olism and elimination. After oral intake of 25 mg of
trans-resveratrol, the absorption was at least 70%, with peak
plasma levels of resveratrol and metabolites of 2 mM and a
plasma half-life of 9 h (47). However, only trace amounts of
resveratrol (,5 ng/ml) could be detected in plasma, while
its glucuronic acid sulfate conjugates were recovered in
4326 Human Molecular Genetics, 2010, Vol. 19, No. 22urine (47). Therefore, a further study to identify stable forms
of resveratrol or its analogy is critical for practical clinic use.
Both AR and PI3K/PTEN/AKT pathways play important
roles regulating prostate cancer proliferation and androgen
independence development. Our previous publication has
reviewed the complex crosstalk between these two pathways
(48). First, AKT directly phosphorylates AR, increasing its
transcriptional activity and stability (9). Also, AKT indirectly
regulates AR transcription through its downstream GSK (49).
So far, however, little was known how nuclear steroid receptor
pathways regulate the PI3K/AKT pathway in prostate cancer
development or progression. Our data here demonstrated that
AR represses PTEN through the 21344 to 21001 promoter
region, indicating a direct link between a nuclear receptor
and PI3K/AKT pathway. Our data suggest a mechanism that
the loss of PTEN expression in hormone-refractory prostate
cancer may be a direct result of AR overexpression and hyper-
activity.
In conclusion, we showed that resveratrol inhibits both
AR-dependent and -independent proliferation in prostate
cancer cells. Importantly, resveratrol is able to induce PTEN
expression via AR inhibition. Furthermore, we showed that,
independent of AR, resveratrol directly inhibits EGFR and
HER2 phosphorylation, with rapid consequent inhibition of
downstream AKT signaling (Fig. 5D). In contrast, resveratrol
inhibits AR-mediated repression of the PTEN promoter with a
later suppressive of AKT (Fig. 5D). Therefore, resveratrol’s
ability of targeting multiple pathways provides us with a stra-
tegic foundation on which to frame the future management of
prostate cancers, especially those that are androgen indepen-
dent and AR negative.
MATERIALS AND METHODS
Cell culture and pharmacological treatments
LNCaP, CWR22rv1 and DU-145 cells were purchased from
the American Type Culture Collection (Manassas, VA,
USA). AR-positive C4-2 cells (UroCor, Oklahoma City, OK,
USA), an androgen-independent sub-line developed from
LNCaP xenografts in castrated nude mice (originating from
Dr Warren Heston). All cells were cultured in ‘complete-
medium’: RPMI 1640 medium with 10% fetal bovine serum.
DU-145 cells were developed from metastatic prostate cancer
tissue and lack AR expression. Bicalutamide (Casodex) (Astra
Zeneca, UK) and 4,5a-DHT (Sigma-Aldrich, St Louis, MO,
USA) were applied per routine of the Silverman and Heston
labs. Formononetin and Biochanin A are from Sigma-Aldrich.
RNA inhibition
Cells were plated in 60 mm dishes and transfected with
50 pmol siRNA. General control was a pool of 4-scrambled
non-speciﬁc siRNA (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Anti-Androgen receptor siRNA (sc-29204, Santa
Cruz Biotechnology) contains a pool of four target-speciﬁc
siRNAs with the following sequences: (A) 5′-CAGUCCC
ACUUGUGUCAAA-3′, (B) 5′-CCUGAUCUGUGGAGA
UGAA-3′, (C) 5′-GUCGUCUUCGGAAAUGUUA-3′, (D)
5′-GACAGUGUCACACAUUGAA-3′.
MTT assay
Cell growth rates were estimated by the MTT assay. Cells
were plated in 24-well plates and treated as indicated. Follow-
ing treatment, each well was incubated with 25 ml of 5 mg/ml
3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl-tetrazolium bromide
(MTT) for 1 h in a CO2 incubator at 378C. The medium was
aspirated and 0.5 ml of DMSO was added per well. Prolifer-
ation rates were estimated by the colorimetric assay of forma-
zan intensity in a plate reader at 560 nm.
Western blotting
Western blotting was performed as described elsewhere (8).
Mouse monoclonal anti-AR and anti-beta-Actin were from
Santa Cruz Biotechnology. Rabbit polyclonal anti-phospho-
EGFR (Tyr1068), anti-total EGFR, anti-phospho-HER2
(Tyr1221/1222), anti-total HER2, anti-phospho-HER3
(Tyr1289), anti-phospho AKT (Ser473), anti-total AKT,
anti-phospho-ERK (Thr202/Tyr204), anti-total ERK, anti-
Androgen Receptor and anti-Hsp90 antibodies were from
Cell Signaling Technology (Beverly, MA, USA). Mouse
monoclonal anti-PSA antibody was from Neomarkers, Lab
Vision Corporation (Fremont, CA, USA).
Promoter activity assay
AR transcriptional activity was measured by Cignal report
assay kit (SA Bioscience, Frederick, MD, USA) as per the
manufacturer’s instructions. We generated PTEN promoters
with variable lengths tagged with the ﬁreﬂy luciferase gene
as described in our previous study (50). Reporter gene activity
was determined by dual luciferase assay. A total of 500 000
cells were plated in 60 mm dishes, co-transfected with 5 mg
of promoter-ﬁreﬂy-luc and 0.1 mg of Renilla-Luc using Lipo-
fectamine 2000 (Invitrogen, Grand Island, NY, USA) accord-
ing to the manufacturer’s recommendations. Cells grown in
complete medium were treated as required for an additional
48 h. After 48 h, cell lysates were prepared for luciferase
analysis using a luciferase enzyme assay system (Promega
Corp., Madison, WI, USA). Each transfection experiment
was performed in triplicate on at least three separate
occasions. Promoter activities were normalized to Renilla luci-
ferase. Results represent an average of independent exper-
iments with data presented as relative luciferase activity
against the means of untreated controls.
Quantitative reverse transcription-polymerase chain
reaction
Quantitative reverse transcription-polymerase chain reaction
(qRT–PCR) to quantitative PSA mRNA expression was
measured using SYBR Green exactly as per the manufacturer’s
speciﬁcations (Applied Biosystem, Foster City, CA, USA).
Expression of GAPDH was used as the internal control. The
primer sequences are as follows: forward: 5′-GGCAGCATT
GAACCAGAGGAG-3′;r e v e r s e :5 ′-GCATGAACTTGGTCA
CCTTCTG-3′.
Human Molecular Genetics, 2010, Vol. 19, No. 22 4327Fluorescence spectroscopy assay
A Synergy-4 Hybrid Multi-Mode spectrometer (Biotek,
Winooski, VT, USA) with Tungsten Halogen high-energy
DPR Xenon ﬂash and deep blocking bandpass ﬁlters was
used to perform all ﬂuorescence measurements. The excitation
wavelength was set at 344 nm and the emission was measured
from 375 to 500 nm. The excitation and emission spectra of
resveratrol, BSA, EGFR and EGFR (672-1210) were recorded
at 238C in PBS (pH 7.0). BSA is from Thermo Fisher Scien-
tiﬁc (Pittsburg, PA, USA). EGFR is from Sigma-Aldrich.
EGFR (His672–Ala1210) is from Cell Signaling Technology.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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